BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:YH42946 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of YH42946\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06616766-2815@assetmemo.bio
DTSTAMP:20261121T005451Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:YH42946: Phase 1/2 readout est. (NCT06616766)
DESCRIPTION:YH42946\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se 1/2\, Open-label\, Multicenter\, FIH Study to Evaluate Safety\, Tolerab
 ility\, PK and Anti-tumor Activity of YH42946\nEstimated primary completio
 n: 15 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/yh4
 2946#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06616766
URL:https://assetmemo.bio/drug/yh42946#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
